Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Abstract

Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed.

Methods: Performance on monthly administrations of the Symbol Digit Modalities Test (SDMT) and the MS Neuropsychological Questionnaire (MSNQ) was assessed in 660 patients with MS in 21 countries (109 sites) for 48 weeks in an open-label, safety-extension study of natalizumab.

Results: At baseline, the cohort’s mean age was 40.1 years, 67.6% were female and the median Expanded Disability Status Scale score was 2.5. Test—retest correlations were high for both SDMT (range 0.89 for weeks 0—4 to 0.96 for weeks 44—48) and MSNQ (0.82 for weeks 0—4 to 0.93 for weeks 44—48). There were no statistically significant effects of geographic region. While SDMT scores improved by 15 points over 48 weeks (p < 0.0001), incremental monthly changes were small (effect size d < 0.3). Similar results were obtained on the MSNQ except that scores moved downward, suggesting fewer cognitive complaints over 48 weeks (p < 0.0001), but again the incremental monthly changes were small (d <-0.2).

Conclusions: These results replicate earlier work in a smaller cohort treated with conventional disease-modifying therapy, and support the reliability of the SDMT and MSNQ as potential screening for monitoring tools for cognition over time.

Keywords

cognition multiple sclerosis screening

Get full access to this article

View all access options for this article.

References

Rao SM , Leo GJ , Bernardin L. and Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction . Neurology 1991; 41: 685-691.

Benedict RH , Cookfair D. , Gavett R. , et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 2006; 12: 549-558.

Benito-Leon J. , Morales JM and Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9: 497-502.

Benedict RHB , Wahlig E. , Bakshi R. , et al. Predicting quality of life in multiple sclerosis: Accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 2005; 231: 29-34.

Amato MP , Ponziani G. , Rossi F. , Liedl CL , Stefanile C. and Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001; 7: 340-344.

Rao SM , Leo GJ , Ellington L. , Nauertz T. , Bernardin L. and Unveragt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692-696.

Benedict RHB , Cox D. , Thompson LL , Foley FW , Weinstock-Guttman B. and Munschauer F. Reliable screening for neuropsychological impairment in MS. Mult Scler 2004; 10: 675-678.

Benedict RHB and Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006; 245: 67-72.

Scherer P. Cognitive screening in multiple sclerosis. J Neurol 2007; 254(Suppl 2): 1126-29.

10.

Foley JF and Brandes DW Redefining functionality and treatment efficacy in multiple sclerosis . Neurology 2009; 72(23 Suppl 5): S1-11.

11.

Benedict RH , Duquin JA , Jurgensen S. , et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 2008; 14: 940-946.

12.

Munschauer F. , Benedict RHB , Granger CV and Niewczyk PM Introduction to best practice recommendations for the selection and management of patients with MS on natalizumab. Mult Scler 2009; 15(S4): 1-6.

13.

Tornatore C. and Clifford DB Clinical vigilance for progressive multifocal leukoencephalopahty in the context of natalizumab use. Mult Scler 2009; 15(S4): 16-25.

14.

Polman CH , O’Connor PW , Havrdova E. , et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.

15.

Rudick RA , Stuart WH , Calabresi PA , et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis . N Engl J Med 2006; 354: 911-923.

16.

Goodman AD , Rossman H. , Bar-Or A. , et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009; 72: 806-812.

17.

Lunceford JK and Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2004; 23: 2937-2960.

18.

D ’Agostino Jr RB Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.

19.

Yanovitzky I. , Zanutto E. and Hornik R. Estimating causal effects of public health education campaigns using propensity scores methodology . Eval Program Plann 2005; 28: 209-220.

20.

Benedict RHB , Munschauer FE , Linn R. , Miller C. , Foley FW and Jacobs LD Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 2003; 9: 95-101.

21.

Duque B. , Sepulcre J. , Bejarano B. , Samaranch L. , Pastor P. and Villoslada P. Memory decline evolves independently of disease activity in MS. Mult Scler 2008; 14: 947-953.

22.

Brochet B. , Deloire MS , Bonnet M. , et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler 2008; 14: 1242-1249.

23.

Howard GS and Dailey PR Response-shift bias: a source of contamination of self-report measures . J Appl Psychol 1979; 64: 144-150.

24.

Schwartz CE Teaching coping skills enhances quality of life more than peer support: results of a randomized trail with multiple sclerosis patients. Health Psychol 1999; 18: 211-220.

25.

Benedict RHB , Carone D. and Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J Neuroimaging 2004 ; 14(Suppl 3): 36S-45S.

26.

Carone D. , Benedict RHB , Munschauer III FE , Fishman I. and Weinstock-Guttman B. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc 2005 ; 11: 574-583.

27.

Benedict RH and Benedict RH B. Effects of using same-versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis . J Int Neuropsychol Soc 2005; 11: 727-736.